Estimating EQ-5D and OAB-5D health state utilities for patients with overactive bladder

Health and Quality of Life Outcomes

Zalmai Hakimi⁴  Isaac Odeyemi²  Jameel Nazir²  Khaled Maman⁵  Samuel Aballéa³  Katia Desroziers¹ 

[1] Creativ-Ceutical USA Inc, Chicago, IL, USA;Astellas Pharma Europe Ltd, Chertsey, UK;Creativ-Ceutical SARL, Paris, France;Astellas Pharma Global Development, Leiden, The Netherlands;Creativ-Ceutical Ltd, London, UK

关键词: Utility assessment;    Quality-adjusted life-years;    OAB-5D;    EQ-5D;    Overactive bladder;    Health-related quality of life;   

Others  :  822072
DOI  :  10.1186/1477-7525-11-200

 received in 2013-05-02, accepted in 2013-11-15,  发布年份 2013

【 摘 要 】

Background

Limited utility data on patients suffering from overactive bladder (OAB) are available in the literature. The objectives of this study were to estimate utility values in patients with OAB using the generic EQ-5D questionnaire and the OAB-5D disease specific questionnaire, to investigate the relationship between utilities and symptoms, and to evaluate the sensitivity of the two instruments to changes in symptom severity.

Methods

Analyses were based on pooled data from three large multicenter randomized 12-week placebo-controlled trials (SCORPIO, ARIES, CAPRICORN). Patients completed a micturition diary, EQ-5D and OAB-q (a quality of life questionnaire from which OAB-5D is derived) at baseline and at weeks 4, 8 and 12. Time trade-off tariffs elicited from UK population were applied to obtain utilities from both instruments. Repeated measures regressions were used to estimate EQ-5D and OAB-5D utilities by micturition frequency and incontinence severity level. As a test of sensitivity of the instruments, utility changes from baseline to week 12 were estimated by symptomatic response (improvement, stable or worsening).

Results

The sample included 4427 patients. Mean utilities (± standard deviation) across all visits were 0.82 (±0.21) for EQ-5D and 0.86 (±0.09) for OAB-5D. Correlation between EQ-5D and OAB-5D was 0.34 (p < 0.0001). Both OAB-5D and EQ-5D utilities increased as OAB symptoms improved. Utility values were similar for severe levels of symptoms, but higher with OAB-5D than with EQ-5D for mild cases. Micturitions and incontinence had similar impact on EQ-5D utilities, but micturitions had greater impact on OAB-5D utilities than incontinence. Changes from baseline in OAB-5D utilities differed significantly according to symptomatic response. Changes in EQ-5D utilities were not significantly associated with changes in micturition frequency and weakly associated with changes in incontinence severity among patients with mild symptoms at baseline.

Conclusions

This study showed that both EQ-5D and OAB-5D can detect changes in severity of OAB, especially in severe cases. However, OAB-5D is more sensitive than EQ-5D in measuring differences between treatments in milder cases. Both OAB-5D and EQ-5D–although leading to different results–may be useful to derive utilities from clinical trial data and perform cost-effectiveness analyses.

Trial registration

Clinical Trials NCT00689104, NCT00662909, NCT00912964.

【 授权许可】

   
2013 Desroziers et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Abrams P, Artibani W, Cardozo L, Dmochowski R, Van Kerrebroeck P, Sand P, International Continence Society: Reviewing the ICS 2002 terminology report: the ongoing debate. Neurourol Urodyn 2009, 28(4):287.
• [2]Brown JS, McGhan WF, Chokroverty S: Comorbidities associated with overactive bladder. Am J Manag Care 2000, 6(Suppl 11):S574-S579.
• [3]Irwin DE, Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, Coyne K, Kelleher C, Hampel C, Artibani W, Abrams P: Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006, 50(6):1306-1314. discussion 1314-5
• [4]National Institute for Health and Clinical Excellence: Guide to the methods of technology appraisal. 2008.
• [5]Gold MR, Siegel JE, Russell LB, Weinstein MC: Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.
• [6]Kobelt G: Economic considerations and outcome measurement in urge incontinence. Urology 1997, 50(Suppl 6A):100-107. discussion 108-10
• [7]Johannesson M, O’Conor RM, Kobelt-Nguyen G, Mattiasson A: Willingness to pay for reduced incontinence symptoms. Br J Urol 1997, 80(4):557-562.
• [8]Yang Y, Brazier J, Tsuchiya A, Coyne K: Estimating a preference-based single index from the overactive bladder questionnaire. Value Health 2009, 12(1):159-166.
• [9]Stolk EA, Busschbach JJ: Validity and feasibility of the use of condition-specific outcome measures in economic evaluation. Qual Life Res 2003, 12(4):363-371.
• [10]Eurich DT, Johnson JA, Reid KJ, Spertus JA: Assessing responsiveness of generic and specific health related quality of life measures in heart failure. Health Qual Life Outcomes 2006, 4:89. BioMed Central Full Text
• [11]McKenna SP, Ratcliffe J, Meads DM, Brazier JE: Development and validation of a preference based measure derived from the Cambridge pulmonary hypertension outcome review (CAMPHOR) for use in cost utility analyses. Health Qual Life Outcomes 2008, 6:65. BioMed Central Full Text
• [12]Young T, Yang Y, Brazier JE, Tsuchiya A, Coyne K: The first stage of developing preference-based measures: constructing a health-state classification using Rasch analysis. Qual Life Res 2009, 18(2):253-265.
• [13]Coyne K, Revicki D, Hunt T, Corey R, Stewart W, Bentkover J, Kurth H, Abrams P: Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res 2002, 11(6):563-574.
• [14]Matza LS, Thompson CL, Krasnow J, Brewster-Jordan J, Zyczynski T, Coyne KS: Test-retest reliability of four questionnaires for patients with overactive bladder: the overactive bladder questionnaire (OAB-q), patient perception of bladder condition (PPBC), urgency questionnaire (UQ), and the primary OAB symptom questionnaire (POSQ). Neurourol Urodyn 2005, 24(3):215-225.
• [15]Coyne KS, Matza LS, Thompson CL: The responsiveness of the Overactive Bladder Questionnaire (OAB-q). Qual Life Res 2005, 14(3):849-855.
• [16]Khullar V, Amarenco G, Angulo JC, Cambronero J, Høye K, Milsom I, Radziszewski P, Rechberger T, Boerrigter P, Drogendijk T, Wooning M, Chapple C: Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol 2013, 63(2):283-295.
• [17]Nitti VW, Auerbach S, Martin N, Calhoun A, Lee M, Herschorn S: Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol 2013, 189(4):1388-1395.
• [18]Herschorn S, Barkin J, Castro-Diaz D, Frankel JM, Espuna-Pons M, Gousse AE, Stölzel M, Martin N, Gunther A, Van Kerrebroeck P: A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β(3)-adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. Urology 2013, 82(2):313-320.
• [19]Dolan P, Jones-Lee M: The time trade-off: a note on the effect of lifetime reallocation of consumption and discounting. J Health Econ 1997, 16(6):731-739.
• [20]Kind P, Hardman G, Macran S: UK Population Norms for EQ-5D. York Centre for Health Economics; 1999. Discussion Paper 172. http://www.york.ac.uk/media/che/documents/papers/discussionpapers/CHE%20Discussion%20Paper%20172.pdf webcite
• [21]Fryback DG, Dunham NC, Palta M, Hanmer J, Buechner J, Cherepanov D, Herrington SA, Hays RD, Kaplan RM, Ganiats TG, Feeny D, Kind P: US norms for six generic health-related quality-of-life indexes from the National Health Measurement study. Med Care 2007, 45(12):1162-1170.
• [22]Kobelt G, Jönsson L, Mattiasson A: Cost-effectiveness of new treatments for overactive bladder: the example of tolterodine, a new muscarinic agent: a Markov model. Neurourol Urodyn 1998, 17(6):599-611.